Phase II trial of sorafenib plus standard therapy in newly diagnosed acute myeloid leukaemia
Treating acute myeloid leukemia with VALOR – vosaroxin in combination with cytarabine
The main challenges facing practitioners treating APL
The differences between biological and chronological age, with their implications on AML treatment
Where will leukemia research go next?